Health Care • Biotechnology: Pharmaceutical Preparations
$28.71 ▼ -0.19
(-0.66%)
MKT CAP: $2.02B • VOL: 806.3K
52W L $16 52W H $31
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$24
MEDIAN
$32
MEAN
$33
HIGH
$39
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ZYME TAPE
ZYME // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $34.74 | $33.02 | 2025-02-14 | $26.13 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $36.17 | $33.88 | 2025-02-06 | $26.99 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $32.73 | $31.58 | 2025-01-29 | $27.56 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $29.28 | — | 2025-01-17 | $28.14 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $25.26 | $27.27 | 2025-01-09 | $25.55 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $34.16 | $29.86 | 2024-12-18 | $24.98 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $27.85 | $29.00 | 2024-12-04 | $26.70 | -4.3% | 48% | C |